Entopsis

Miami, United States Founded: 2011 • Age: 15 yrs
Diagnostic devices for health monitoring are developed using specialized slides.

About Entopsis

Entopsis is a Technology company based in Miami (United States) founded in 2011. Diagnostic devices for health monitoring are developed using specialized slides. Entopsis has raised $1.05 million across 3 funding rounds from investors including Krillion Ventures, G3 Capital Partners and Breakout Ventures. Entopsis offers products and services including NuTec, OpsisDx, and PCRopsis Oral Rinse. Its focus areas include High Tech, Nanotechnology, Nanoenabled Products and Life Science. Its legal entity is Entopsis LLC. Its competitors include BioMedomics, Maxwell Sensors and NanoCytomics; 1 of its 3 listed competitors has raised funding.

Company details

Specialized glass slides known as NUTEC were developed by the company, founded in 2011 and based in Miami, United States, to enable detection of DNA, RNA, proteins, and small molecules through colorimetric changes. Software utilizing machine learning is provided for data analysis. Operations focus on diagnostics in oncology, autoimmune conditions, and rare diseases within the health technology sector.

Operational Areas
Key Metrics
  • Total Equity Funding
    $1.05M (USD)

    in 3 rounds

  • Latest Funding Round
    $250K (USD), Seed

    Dec 2016

  • Investors

Products & Services of Entopsis

Entopsis offers a comprehensive portfolio of products and services, including NuTec, OpsisDx, and PCRopsis Oral Rinse.

NuTec
Diagnostic Device

Device for unbiased molecular identification in health monitoring.

OpsisDx
Colorimetric Platform

Platform for detecting and distinguishing multiple analytes in samples.

PCRopsis Oral Rinse
Sample Collection Device

Tool for simple oral sample collection and transportation for testing.

Apps and channels of Entopsis

its YouTube channel Entopsis has 9 subscribers and 4 videos.

Entopsis
YouTube 9 subscribers 4 videos Science & Technology
Open channel

Videos from Entopsis

The most watched videos on Entopsis's YouTube channel, Entopsis (9 subscribers). Click a video to play it here.

A Sit Down with the Co-Founder of Entopsis
769 views
Entopsis Explainer Video
129 views
Genurine Explainer Video
98 views
Genurine Explainer Vid
43 views

More on Entopsis.

Funding Insights of Entopsis

Entopsis has successfully raised a total of $1.05M across 3 strategic funding rounds. The most recent funding activity was a Seed round of $250 thousand completed in December 2016. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

  • Total Funding $1.05M
  • Total Rounds 3
  • Last Round Seed β€” $250,000
  • First Round $160,000

    (May 2012)

  • Investors Count 3

All 3 funding rounds of Entopsis with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.

DateAmountTransaction NameValuationLead InvestorsInvestors
Dec 2016$250,000Seed––
–
Mar 2015$800,000Seed–Krillion Ventures
May 2012$160,000Grant––
Valuation history

3 investors in total: 3 institutional.

Investors in Entopsis

Entopsis has secured backing from 3 investors, including venture fund investors. Prominent investors backing the company include Krillion Ventures, G3 Capital Partners and Breakout Ventures.

All
Venture Fund
InvestorDescriptionFounded YearDomainLocation
A venture capital fund based in Miami is operated.
2022krillionventures.comMiami, United States
Limited information is provided about G3 Capital Partners.
g3capitalpartners.com
Early-stage science-driven companies are supported through venture capital investments.
breakoutlabs.org
Premium access

Investor details for Entopsis

The complete investor list, round-by-round participation and investor portfolios require an active premium plan.

  • Complete investor list
  • Round participation
  • Investor portfolios
  • Co-investor network

Verified entity values are shown only after access is granted.

People of Entopsis

8 people are tracked at Entopsis (1 in leadership, 6 in board & advisors, 1 in team).

NameRoleGroup
George Huang
CFOLeadership
Peter Chang
Clinical AdvisorBoard & advisors
Davinder Grover
Clinical AdvisorBoard & advisors
Mari Heghinian
MemberBoard & advisors
Erika Arias
MemberBoard & advisors
Monica Goldberg
Clinical AdvisorBoard & advisors
Juan Ayala Haedo
MemberBoard & advisors
Ian Cheong
CoFounderTeam
Premium access

Complete people profiles for Entopsis

Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.

  • Full employee list
  • Team structure
  • Board tenure
  • Professional contacts

Verified entity values are shown only after access is granted.

Timeline of Entopsis

3 dated milestones of Entopsis across 5 years, from founding to its latest funding, stage changes and deals.

  1. Founded Entopsis is founded.
  2. Funding First funding round of $160K.
  3. Funding Latest funding round, Seed, of $250K.

Competitors of Entopsis

Entopsis has 3 listed competitors in our database, 1 of them funded. They include BioMedomics, Maxwell Sensors and NanoCytomics.

Company NameDomainFoundedHQ LocationTotal fundingEmployeesDescription
biomedomics.com2006Durham, United States$1.5M14
Point-of-care diagnostic systems for blood-based disorders are developed.
maxwellsensors.com1998Santa Fe Springs, United States24
nano-cytomics.com2011Evanston, United States
Imaging-based diagnostic devices for cancer are developed.
Premium access

Detailed competitors of Entopsis

The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.

  • Full competitor set
  • Operating metrics
  • Benchmarks
  • Competitive positioning

Verified entity values are shown only after access is granted.

Top companies in Nanotechnology

3 companies that operate in the same segment as Entopsis (Nanotechnology) in United States, ranked by their profile score on The Company Check.

CompanyDescriptionFoundedLocationTotal fundingRevenueEmployees
Developer of technologies for analysis of genetic variation and function
1993San Diego, California, United StatesUSD 28 MUSD 34.92 M9,630
RNA interference-based therapeutics are developed for multiple disorders.
2002Cambridge, Massachusetts, United StatesUSD 17 MUSD 3.71 B2,230
Aerogel-based thermal insulation solutions are provided for energy conservation.
2001United StatesUSD 198.35 MUSD 271.1 M554
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track β€” from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • βœ“
    Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • βœ“
    Full access to every database India & global coverage, advanced filters and rich profile details
  • βœ“
    Always-on access from your team account Single premium plan for everything you see on the portal

Related news about Entopsis

Premium access

Complete news archive for Entopsis

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Entopsis

Entopsis was founded in 2011 and raised its 1st funding round 1 year after it was founded.

Entopsis is headquartered in Miami, United States. It is registered at Miami, Florida, United States.

Entopsis is a funded company, having raised a total of $1.05M across 3 funding rounds to date. The company's 1st funding round was a Grant of $160K, raised on May 2012.

Specialized glass slides known as NUTEC were developed by the company, founded in 2011 and based in Miami, United States, to enable detection of DNA, RNA, proteins, and small molecules through colorimetric changes. Software utilizing machine learning is provided for data analysis. Operations focus on diagnostics in oncology, autoimmune conditions, and rare diseases within the health technology sector.

Entopsis's top competitors include BioMedomics, NanoCytomics and Maxwell Sensors.

Entopsis offers NuTec, OpsisDx, and PCRopsis Oral Rinse.

Entopsis has 3 investors. Key investors include Krillion Ventures, G3 Capital Partners, and Breakout Ventures.

Entopsis operates through Entopsis Llc.

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available